A detailed history of Sargent Bickham Lagudis LLC transactions in Nkarta, Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 100 shares of NKTX stock, worth $571. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$571
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 23, 2023

BUY
$5.14 - $14.35 $514 - $1,435
100 New
100 $0

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $278M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.